Posts Tagged ‘Pfizer’
FDA approves new Pfizer, Moderna vaccines as COVID wave increases – Nick Landekic
by Nick Landekic, contributing The U.S. Food and Drug Administration on Thursday approved the latest reformulated COVID vaccines, making it possible for people over 6 months of age to get additional protection in the midst of the ongoing and still increasing surge this summer of the virus. What you need to know: We are now…
Read MoreNew updated COVID-19 Boosters now available in Rhode Island
Updated COVID-19 Booster Doses to be Available in Rhode Island Bivalent boosters to target two strains of COVID-19 With a new, more comprehensive COVID-19 booster dose now authorized and recommended by federal health officials, these updated booster shots will start to become available in Rhode Island this week and next. “This is a good reminder…
Read MoreModerna and Pfizer COVID vaccine for children 6 months+ gets FDA approval
Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to 6 months of age. CVS has announced it will provide vaccines for children 18 months and older – otherwise parents can access their…
Read More3 small-dose COVID vaccine for children 6 mos-5 yrs from Pfizer/BioNTech
Pfizer and BioNTech today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to elicit a strong immune response,…
Read MoreMoving ahead with COVID vaccines for young children
Moderna (6 mos-5 yrs) and Pfizer (5-11 yrs booster) are next up seeking approval as vaccines. The Moderna will be 2 shots, 4 weeks apart, at 25% strength of an adult shot for children 6 mos to 5 years. Pfizer’s approval request is for a booster for children 5 to 11. After the age of…
Read MoreWHO recommends Paxlovid for treating COVID-19 worldwide. Pfizer must increase its availability.
The WHO issues recommendations on COVID-19 treatment with Paxlovid.
Read MoreEmergency approval expected for 4th Pfizer shot for those over 65
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults Pfizer and BioNTech today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age…
Read MoreCOVID-19 vaccine for children 6 months to 5 coming as FDA asks Pfizer and BioNTech to seek approval
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA Once approval is received, this immunization will take its place among 16 others children are given, some required for attendance in school. With pediatric COVID-19 cases surpassing…
Read MoreExpanded use of Pfizer boosters for some children approved by FDA.
The 3-step process of to bring vaccinations to the American public has become familiar. First, the FDA acts through either an EUA or general approval, then the AICP, a committee of the CDC grants approval, followed by the 3rd step of full CDC approval. At that point – all expected in this latest EUA to…
Read MoreNEW: Pfizer antiviral pill, Paxlovid, showing 88% reduced risk of hospitalization/death if taken within 5 days of first symptom
Pfizer today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial of its novel COVID-19 oral antiviral candidate PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). These results were consistent with the interim analysis announced in November 2021, showing…
Read More